Open AccessAdditional Features in the Treatment of Patients with Chronic Heart Failure. From EMPA-REG OUTCOME Study to EMPEROR-REDUCED Study. Resolution of the On-line Scientific Meeting of Moscow Experts
Author(s) -
A. Lebedeva,
O.M. Koteshkova Koteshkova,
О. Н. Джиоева,
S. R. Gilyarevsky,
Т. М. Ускач,
Mariovikova,
Ya. A. Orlova,
Viktor Y. Kalashnikov,
Dmitry Privalov,
N. A. Ananicheva,
M. Yu. Gilyarov,
А. Д. Эрлих
Publication year - 2021
Publication title -
racionalʹnaâ farmakoterapiâ v kardiologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.161
H-Index - 9
eISSN - 2225-3653
pISSN - 1819-6446
DOI - 10.20996/1819-6446-2021-01-03
Subject(s) - medicine , empagliflozin , emperor , ejection fraction , heart failure , empa , clinical practice , cardiology , intensive care medicine , family medicine , diabetes mellitus , endocrinology , ancient history , chemistry , mineralogy , electron microprobe , history , type 2 diabetes mellitus
The results of the international multicenter study EMPEROR-REDUCED were reviewed the on-line scientific meeting of Moscow experts on October 30, 2020. Some proposals and recommendations for further study of the cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with chronic heart failure with reduced ejection fraction were accepted.